Korro Bio (KRRO) Net Income towards Common Stockholders (2018 - 2026)
Korro Bio (KRRO) posted Net Income towards Common Stockholders of -$19.6 million for Q1 2026, down 121.12% on a QoQ basis from $92.9 million in Q4 2025, and up 16.09% year-over-year from -$16.9 million in Q1 2025.
Korro Bio (KRRO) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Korro Bio's Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at -$19.6 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 16.09% year-over-year to -$19.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.4 million (up 852.88% YoY) and the FY2025 annual result came in at $25.7 million, up 31807.41% from the prior year.
- Net Income towards Common Stockholders was -$19.6 million for Q1 2026 at Korro Bio, down from $92.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $92.9 million in Q4 2025 and bottomed at -$25.8 million in Q2 2025.
- A 5-year average of -$7.8 million and a median of -$19.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders tumbled 511.02% — and 2024, when it jumped 345.03%.
- Korro Bio's Net Income towards Common Stockholders stood at $6.2 million in 2022, then tumbled by 511.02% to -$25.4 million in 2023, then soared by 345.03% to $62.3 million in 2024, then soared by 49.12% to $92.9 million in 2025, then sank by 121.12% to -$19.6 million in 2026.
- Business Quant data shows KRRO's Net Income towards Common Stockholders at -$19.6 million in Q1 2026, $92.9 million in Q4 2025, and -$18.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | -0.68 |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Korro Bio | 122.37 Mn | 8.40 Mn | - | -19.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.63 Mn |
| Dec 31, 2025 | 92.90 Mn |
| Sep 30, 2025 | -18.06 Mn |
| Jun 30, 2025 | -25.77 Mn |
| Mar 31, 2025 | -23.39 Mn |
| Dec 31, 2024 | 62.30 Mn |
| Sep 30, 2024 | -21.00 Mn |
| Jun 30, 2024 | -21.83 Mn |
| Mar 31, 2024 | -19.56 Mn |
| Dec 31, 2023 | -25.43 Mn |
| Sep 30, 2023 | -18.49 Mn |
| Jun 30, 2023 | -17.65 Mn |
| Mar 31, 2023 | -19.61 Mn |
| Dec 31, 2022 | 6.19 Mn |
| Sep 30, 2022 | -19.55 Mn |
| Jun 30, 2022 | -21.29 Mn |
| Mar 31, 2022 | -23.39 Mn |
| Dec 31, 2021 | -21.50 Mn |
| Sep 30, 2021 | -25.16 Mn |
| Jun 30, 2021 | -17.66 Mn |